News & Events


  • Chemomab doses first subject in a phase 1 clinical trial of Subcutaneous injected CM-101 in healthy volunteers

  • Chemomab appoints Bryan Jennings as Chief Financial Officer

  • Chemomab was granted an Orphan Drug Designation from the FDA for the treatment of Primary Sclerosing Cholangitis

  • Chemomab successfully completed Phase 1 in healthy volunteers, achieving its primary endpoint of safety, pharmacokinetics and pharmacodynamics

  • Chemomab completed a $10 million series B fund raising supported by Orbimed Israel, Peter Thiel, SBI Japan-Israel innovation Fund and Milestone venture.

  • Chemomab received OCS grant for the development of the CM101 program.

  • Chemomab initiated its first in man clinical trial to test the safety, pharmacokinetic and pharmacodynamic profile of its lead drug CM101 in healthy volunteers.

  • Chemomab assembles advisory board meeting with Scleroderma key opinion leaders to discuss the outline of its clinical trial in Washington.

  • Chemomab receives formal scientific advice from EMA for pre-clinical and clinical development of its lead first in class monoclonal antibody CM101.

  • Chemomab is granted approval for its patent: ” Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders ” in USA, Europe and Israel.

  • Chemomab has engaged CMC Biologics for a full manufacturing program to generate GMP material for clinical trials.

  • Chemomab received a second FDA approved orphan drug designation, for idiopathic pulmonary fibrosis treatment with CM101.

  • Chemomab was granted orphan drug designation by the FDA, to treat systemic sclerosis patients with CM101.

  • Chemomab received an orphan drug designation approval from the EMA for CM101 treatment in systemic sclerosis.


  • Chemomab to present “CM-101 a novel CCL24 blocking monoclonal antibody attenuates HSC activation in vitro and reduces fibrosis in the TAA mice model” at AASLD International Liver Meeting in Boston, 2019

  • Chemomab to Present “CM101, A novel CCL24 blocking antibody, suppresses hepatic injury and fibrosis in experimental models of NASH and liver fibrosis” at AASLD international Liver meeting in San Francisco 2018

  • Chemomab presents “A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis” at EASL International Liver Congress 2018.

  • Chemomab to present ” CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model” at AASLD’s Liver Meeting® 2017.

  • Chemomab presents “Circulating levels of the chemokine CCL24 and its receptor in patients with non-alcoholic fatty liver disease” in the Israeli Liver convention.